KR20180135912A - 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법 - Google Patents

개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법 Download PDF

Info

Publication number
KR20180135912A
KR20180135912A KR1020187031479A KR20187031479A KR20180135912A KR 20180135912 A KR20180135912 A KR 20180135912A KR 1020187031479 A KR1020187031479 A KR 1020187031479A KR 20187031479 A KR20187031479 A KR 20187031479A KR 20180135912 A KR20180135912 A KR 20180135912A
Authority
KR
South Korea
Prior art keywords
virus
live
concentration
composition
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187031479A
Other languages
English (en)
Korean (ko)
Inventor
질 앤 리벤굿
티모시 듀엔 파웰
Original Assignee
다케다 백신즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 백신즈 인코포레이티드 filed Critical 다케다 백신즈 인코포레이티드
Publication of KR20180135912A publication Critical patent/KR20180135912A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187031479A 2016-03-31 2017-03-27 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법 Ceased KR20180135912A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316262P 2016-03-31 2016-03-31
US62/316,262 2016-03-31
PCT/US2017/024365 WO2017172643A1 (en) 2016-03-31 2017-03-27 Compositions and methods for stabilizing alphaviruses with improved formulations

Publications (1)

Publication Number Publication Date
KR20180135912A true KR20180135912A (ko) 2018-12-21

Family

ID=58537071

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187031479A Ceased KR20180135912A (ko) 2016-03-31 2017-03-27 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법

Country Status (19)

Country Link
US (2) US10632184B2 (enExample)
EP (1) EP3436063A1 (enExample)
JP (1) JP2019513138A (enExample)
KR (1) KR20180135912A (enExample)
CN (1) CN109069614A (enExample)
AU (1) AU2017241590A1 (enExample)
BR (1) BR112018069035A2 (enExample)
CA (1) CA3019529A1 (enExample)
CO (1) CO2018010357A2 (enExample)
CR (1) CR20180456A (enExample)
DO (1) DOP2018000211A (enExample)
EC (1) ECSP18081486A (enExample)
MX (1) MX2018011837A (enExample)
NI (1) NI201800096A (enExample)
PE (1) PE20190149A1 (enExample)
PH (1) PH12018502119A1 (enExample)
SG (1) SG11201808458QA (enExample)
SV (1) SV2018005747A (enExample)
WO (1) WO2017172643A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087188A1 (en) 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
WO2021028406A1 (en) * 2019-08-09 2021-02-18 Valneva Se Chikungunya vaccine formulations
CA3149932A1 (en) * 2019-08-09 2021-02-18 Valneva Se Single shot chikungunya virus vaccine
PH12022550939A1 (en) * 2019-10-25 2024-02-12 Bavarian Nordic As Chikungunya virus-like particle vaccine and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545555A (en) 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
BRPI0716145B1 (pt) 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US10137186B2 (en) 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗

Also Published As

Publication number Publication date
PE20190149A1 (es) 2019-01-22
JP2019513138A (ja) 2019-05-23
BR112018069035A2 (pt) 2019-01-29
WO2017172643A1 (en) 2017-10-05
CO2018010357A2 (es) 2019-05-21
EP3436063A1 (en) 2019-02-06
SV2018005747A (es) 2019-03-28
NI201800096A (es) 2019-02-01
MX2018011837A (es) 2019-02-13
CA3019529A1 (en) 2017-10-05
ECSP18081486A (es) 2019-01-31
US20190111124A1 (en) 2019-04-18
DOP2018000211A (es) 2018-12-31
US10632184B2 (en) 2020-04-28
PH12018502119A1 (en) 2019-07-15
US20200306361A1 (en) 2020-10-01
CN109069614A (zh) 2018-12-21
SG11201808458QA (en) 2018-10-30
AU2017241590A1 (en) 2018-10-11
CR20180456A (es) 2019-01-09

Similar Documents

Publication Publication Date Title
JP6817370B2 (ja) 弱毒生ウイルス組成物
US11701421B2 (en) Compositions and methods for stabilizing flaviviruses with improved formulations
DK2099485T3 (en) Alphavirus and alphavirus replica particle formulations and associated methods
US10806781B2 (en) Compositions and methods for live, attenuated alphavirus formulations
US20200306361A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
MXPA05008695A (es) Estabilizacion de composiciones virales.
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200327

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210528

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210528

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I